© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis
aDepartment of Pathobiology and the Interdisciplinary Graduate Program in Nutritional Sciences, University of Washington, Seattle, WA, USA
bInnere Medizin III, Universität Heidelberg, Heidelberg, Germany
*Corresponding author. Department of Pathobiology and the Interdisciplinary Graduate Program in Nutritional Science, P.O. Box 353410, University of Washington, Seattle, WA 98195, USA. Tel.: +1-206-543-1738; fax: +1-206-616-1245.Email address: ssmjm{at}u.washington.edu
Objective: Inflammation contributes to atherosclerotic plaque initiation and progression. Recent studies suggest that anti-inflammatory drugs such as cyclooxygenase-2 (Cox-2) inhibitors have anti-atherogenic effects. The current study was designed to investigate whether administration of a Cox-2 inhibitor to older apolipoprotein E deficient (apo E–/–) mice with established lesions alters the composition and increases the stability of the lesions. Methods and results: The Cox-2 inhibitor Celecoxib was administered in chow to 26-week-old, male, apo E–/– mice exhibiting advanced, unstable atherosclerotic lesions within the innominate/brachiocephalic artery. Mice administered Celecoxib had no significant changes in serum cholesterol or the average cross sectional area of atherosclerotic lesion in the innominate artery after 15 weeks of treatment in comparison to non-treated control mice. Histological analyses of sections of the innominate artery demonstrated no significant changes in the frequency of markers of advanced and unstable atherosclerotic plaques, including intra-plaque hemorrhage, vascular calcification, thinning of the fibrous cap, size of the necrotic core and macrophage content. There were also no significant differences in the content of Cox-2 within the lesions. Quantitative real time polymerase chain reaction with mRNA isolated from the aorta of each mouse revealed no significant changes in the expression of tissue factor and inducible nitric oxide synthase. However, mRNA levels for MCP-1 were increased fivefold following 15 weeks of treatment with Celecoxib in comparison to non-treated control mice. Conclusions: These data suggest that Celecoxib has no effect on the composition of advanced atherosclerotic lesions in older apo E–/– mice.
KEYWORDS Atherosclerosis; Cyclooxygenase-2; Infection/inflammation; Macrophages
Time for primary review 14 days.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Gitlin and C. D. Loftin Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice Cardiovasc Res, February 1, 2009; 81(2): 400 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Jackson, M. R. Bennett, E. A.L. Biessen, J. L. Johnson, and R. Krams Assessment of Unstable Atherosclerosis in Mice Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 714 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Antman, J. S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K. A. Taubert Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association Circulation, March 27, 2007; 115(12): 1634 - 1642. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Jackson Ruptures of Delight?: A New Mouse Model of Plaque Rupture. Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1191 - 1192. [Full Text] [PDF]
|
|
|
|
|
|
W.A. Boisvert, D.M. Rose, A. Boullier, O. Quehenberger, A. Sydlaske, K.A Johnson, L.K. Curtiss, and R. Terkeltaub Leukocyte Transglutaminase 2 Expression Limits Atherosclerotic Lesion Size Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 563 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Harris and M. D. Breyer Update on Cyclooxygenase-2 Inhibitors Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 236 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Soumian, R Gibbs, A Davies, and C Albrecht mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease J. Clin. Pathol., December 1, 2005; 58(12): 1255 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Bennett, A. Daugherty, D. Herrington, P. Greenland, H. Roberts, and K. A. Taubert The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Science Advisory From the American Heart Association Circulation, April 5, 2005; 111(13): 1713 - 1716. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Egan, M. Wang, M. B. Lucitt, A. M. Zukas, E. Pure, J. A. Lawson, and G. A. FitzGerald Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism Circulation, January 25, 2005; 111(3): 334 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Meir and E. Leitersdorf Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1006 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Calabrese, A. C van der Wal, and M. Levi Infection and inflammation in the cardiovascular system Cardiovasc Res, October 15, 2003; 60(1): 1 - 4. [Full Text] [PDF]
|
|